Tag: gastroenteropancreatic neuroendocrine tumors

10 Highlights of the Year 2014 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2014, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…

Breaking News: US FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors

December 16, 2014: The US Food and Drug Administration (FDA) today approved “lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic…

New Feature for Medical Professionals on Carcinoid Cancer Foundation Website

The Carcinoid Cancer Foundation is pleased to announce that a new feature for the medical community has been added to its website, www.carcinoid.org.  The section is entitled Continuing Medical Education (CME).   Upcoming events include:

• The Penn